We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.
On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.